Source-grounded facts extracted from Bicara Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Bicara Therapeutics Inc. reported the first quarter ended March 31, 2026 results: net income Net loss totaled $56.2 million for the first quarter of 2026.
“Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026”
Bicara Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti.
“On March 30, 2026, Bicara Therapeutics Inc. (the "Company") issued a press release announcing its financial results and business highlights for the fiscal year and quarter ended December 31, 2025.”
Bicara Therapeutics Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (effective 2026-02-24).
“On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”)”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.